Artificial Intelligence | Machine Learning | Machine Perception BlackThorn Therapeutics | Neurobehavioral Disorder Drug Development


Enterprise, Healthcare, Biotechnology, Therapeutics, Data Science, Drug Development San Francisco, CA, United States

BlackThorn Therapeutics

Artificial Intelligence | Machine Learning | Machine Perception


BlackThorn Therapeutics | Neurobehavioral Disorder Drug Development

BlackThorn Therapeutics

Healthcare, Biotechnology, Therapeutics, Data Science, Drug Development


San Francisco, CA, United States

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. With pathfinder™, our computational psychiatry platform, our approach is based on generating a quantitative, brain-based understanding of neurobehavioral disorders. These data-driven insights are applied to create treatments targeted to biologically-based subtypes of patients to increase the precision of therapeutic intervention. Our clinical pipeline is designed to restore balance to dysregulated brain circuits and empower individuals with CNS disorders to live better lives. BlackThorn is headquartered in San Francisco, California. For more information, please visit blackthornrx.com.

 
 

   Total Funding: $138,000,000

   Funding Stage: Series B

   Business Stage: Scaling Up

   Market: B2B

   Company Size: 26 to 50

   Founded: 2015

 
 

For AI Startup Founders

Get introduced to VC/PE/CVC investors

For Investors at VC/PE firms

Get introduced to AI Startup founders or founders at BlackThorn Therapeutics

 
 
 
Oscar Rodriguez


Oscar Rodriguez
Co-chair

Jane Tiller


Jane Tiller
CMO

 
 

BlackThorn Therapeutics - AI Startup | AI Startup Profile Powered by Appengine AI | Appengine AI - AI Ecosystem of 12,000+ AI Startups appengine.ai BlackThorn Therapeutics - Manage Profile

 
 
 
appengine.ai

World's Most Promising AI Startups





World's Leading AI Ecosystem of AI Startups, Founders, Investors, and AI Professionals


Get Started